Abstract:Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors in combination with platinum-based chemotherapies are currently established as standard care of first-line treatment in NSCLC regardless of PD-L1 expression.1Gandhi L. Rodríguez-Abreu D. Gadgeel S. et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.N Engl J Med. 2018; 378: 2078-2092Google Scholar, 2Paz-Ares L. Luft A. Vicente D. et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.N Engl J Med. 2018; 379: 2040-2051Google Scholar, 3Socinski M.A. Jotte R.M. Cappuzzo F. et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.N Engl J Med. 2018; 378: 2288-2301Google Scholar, 4West H. McCleod M. Hussein M. et al.Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2019; 20: 924-937Google Scholar However, the development and the successful outcomes of cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibition combined with PD-1 or PD-L1 inhibitors in lung cancer urged clinical researchers to further test these agents with chemotherapy (chemo). In this issue of the journal, Leighl et al.5Leighl N.B. Laurie S.A. Goss G.D. et al.CCTG BR34: a randomized phase II trial of durvalumab and tremelimumab +/− platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.J Thorac Oncol. 2022; 17: 434-445Google Scholar reported a randomized phase 2 trial of durvalumab and tremelimumab with or without platinum-based chemo in patients with metastatic NSCLC (CCTG BR34). In this trial, the addition of chemo to durvalumab plus tremelimumab in the first-line treatment of stage IV NSCLC did not improve overall survival (OS) compared with durvalumab plus tremelimumab (16.6 mo versus 14.1 mo, hazard ratio [HR] = 0.88, p = 0.46), but progression-free survival (PFS) was significantly longer with the addition of chemo than with immunotherapy alone (7.7 mo versus 3.2 mo, HR = 0.67, p = 0.003). Durvalumab has been approved since 2017 to treat patients with unresectable stage III NSCLC whose disease has not progressed after concurrent platinum-based chemo and radiation therapy.6Antonia S.J. Villegas A. Daniel D. et al.Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.N Engl J Med. 2018; 379: 2342-2350Google Scholar,7Antonia S.J. Villegas A. Daniel D. et al.Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer.N Engl J Med. 2017; 377: 1919-1929Google Scholar It has been hypothesized that the combination with tremelimumab may amplify antitumor T-cell responses through an immune checkpoint blockade and provide additive or synergistic activity.8Chaft J. Cho B.C. Ahn M.J. et al.Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC.Cancer Res. 2018; 78: CT113Google Scholar The first clinical study performed to evaluate such a hypothesis and the safety of the scheme was performed by Antonia et al.9Antonia S. Goldberg S.B. Balmanoukian A. et al.Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.Lancet Oncol. 2016; 17: 299-308Google Scholar in 2016; the authors evaluated durvalumab plus tremelimumab in 102 patients with immunotherapy-naive advanced NSCLC in a nonrandomized study at five cancer centers in the United States. Investigator-confirmed objective responses were achieved by 6 of 26 patients in the combined cohort (23%, 95% confidence interval: 9–44%). Over approximately 2 years, treatment-related grade 3 and 4 adverse events were observed in 36% of the cases. The authors concluded that durvalumab plus tremelimumab combination revealed a manageable tolerability profile; interestingly, clinical activity was noted regardless of PD-L1 expression. The randomized phase 3 MYSTIC clinical trial investigated whether durvalumab with or without tremelimumab in first-line treatment compared with chemo improved survival in patients with metastatic NSCLC.10Rizvi N.A. Cho B.C. Reinmuth N. et al.Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 661-674Google Scholar In this study, first-line treatment with durvalumab did not significantly improve OS compared with chemo (16.3 mon versus 12.9 mo, HR = 0.76, p = 0.04 [nonsignificant]), but it was associated with a lower risk of death, whereas durvalumab plus tremelimumab did not significantly improve OS (p = 0.2) or PFS (p = 0.71) compared with chemo. However, first-line treatment with nivolumab plus ipilimumab (CheckMate 227)11Hellmann M.D. Paz-Ares L. Bernabe Caro R. et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.N Engl J Med. 2019; 381: 2020-2031Google Scholar resulted in a longer OS compared with chemo in patients with advanced-stage NSCLC, independent of the PD-L1 expression level. The median duration of response was also longer with nivolumab plus ipilimumab than chemo.11Hellmann M.D. Paz-Ares L. Bernabe Caro R. et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.N Engl J Med. 2019; 381: 2020-2031Google Scholar Interestingly, the U.S. Food and Drug Administration has approved this regimen for patients with tumor cell PD-L1 positivity of greater than or equal to 1% according to the Dako 28-8 assay (Agilent, Santa Clara, CA). Finally, the phase 3 KEYNOTE-598 trial12Boyer M. Şendur M.A. Rodríguez-Abreu D. et al.Pembrolizumab plus ipilimumab or placebo for metastatic non− small-cell lung cancer with PD-L1 tumor proportion score ≥50%: randomized, double-blind phase III KEYNOTE-598 study.J Clin Oncol. 2021; 39: 2327-2338Google Scholar provides a comparison of the efficacy of combined pembrolizumab plus ipilimumab with that of pembrolizumab monotherapy in patients with PD-L1–high (≥50%) advanced-stage NSCLC without EGFR or anaplastic lymphoma kinase alterations. No significant difference in median OS was observed between the pembrolizumab plus ipilimumab and pembrolizumab plus placebo arms (21.4 mo, HR = 1.08, p = 0 .74), respectively. There is emerging evidence that adding anti–CTLA-4 to anti–PD-1/PD-L1 plus chemo might confer additional clinical and longer survival benefits in NSCLC. CheckMate 9LA13Paz-Ares L. Ciuleanu T.E. Cobo M. et al.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 198-211Google Scholar revealed considerable improvement in the primary end points in the experimental group compared with the control group. The median OS was 15.6 months in the doublet immunotherapy–chemo arm and 10.9 months in the chemo arm. A 12-month OS rate benefit was observed in the experimental group when compared with the control group (63% versus 47%). The participants in the experimental group experienced improved PFS compared with those in the control group (6.8 mo versus 5.0 mo). Thus, CheckMate 9LA confirmed the survival benefit of double immunotherapy plus chemo. The positive results of the clinical trial led the U.S. Food and Drug Administration to approve nivolumab combined with ipilimumab and two cycles of chemo for the treatment of advanced NSCLC without targetable driver mutations. The POSEIDON trial14Johnson M. Cho B.C. Luft A. et al.Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. Presented at: 2021 IASLC World Conference on Lung Cancer.September 8-14, 2021Google Scholar evaluated durvalumab with or without tremelimumab, in combination with investigator-choice chemo regimens as first-line treatment for metastatic NSCLC. In the POSEIDON trial, first-line durvalumab plus tremelimumab and chemo revealed statistically significant and clinically meaningful improvements in both PFS and OS versus chemo alone in patients with metastatic NSCLC. The OS and PFS benefits were more prominent among nonsquamous patients (than squamous patients) histology. These findings could add to our understanding of immune checkpoint inhibitors in NSCLC and dampen enthusiasm for the approach that combined chemo and immunotherapy. Previous studies have revealed that the early survival curves of patients who receive immunotherapy alone are entangled with, or are lower than, those of chemo-treated patients.15Rittmeyer A. Barlesi F. Waterkamp D. et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Lancet. 2017; 389: 255-265Google Scholar,16Borghaei H. Paz-Ares L. Horn L. et al.Nivolumab versus docetaxel in Advanced nonsquamous Non-Small-Cell Lung Cancer.N Engl J Med. 2015; 373: 1627-1639Google Scholar CheckMate 9LA revealed that the OS and PFS curves of the combination treatment group were separated from those of the chemo group at an early point without crossover. The addition of chemo may benefit those patients who have not benefited from immunotherapy at the beginning of the treatment. The effect of immunotherapy alone may be restricted owing to extensive tumor antigen heterogeneity that prevents the immune system from triggering effective attacks.17Leonetti A. Wever B. Mazzaschi G. et al.Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.Drug Resist Updat. 2019; 46: 100644Google Scholar Chemo, even at a low dose, has synergistic effects when combined with immunotherapy. Chemo can release antigens, induce immunogenic cell death, activate the antitumor immune response, and increase PD-L1 expression on malignant cells.18Wang Q. Ju X. Wang J. Fan Y. Ren M. Zhang H. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies.Cancer Lett. 2018; 438: 17-23Google Scholar,19Kyi C. Postow M.A. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.Immunotherapy. 2016; 8: 821-837Google Scholar In summary, both POSEIDON and CheckMate 9LA have confirmed that the addition of chemo cycles in double immunotherapy has avoided the typical early intersection of the curves, saving those patients who do not respond to immunotherapy alone. Finally, the CCTG BR34 trial5Leighl N.B. Laurie S.A. Goss G.D. et al.CCTG BR34: a randomized phase II trial of durvalumab and tremelimumab +/− platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.J Thorac Oncol. 2022; 17: 434-445Google Scholar further indicated a question: what is the role of chemo in the dual immune checkpoint inhibition era? For patients with low or absent PD-L1 expression, or those with high PD-L1 expression with an immediate need for cytoreduction? PD-1 or PD-L1 antibodies plus histology-selected platinum-doublet chemotherapies have been approved as first-line therapy. Meanwhile, which patients will benefit from CTLA-4 plus PD-1 or PD-L1 plus chemo? We tend to favor patients with PD-L1–negative squamous carcinoma with best HR (Table 1, from CheckMate-9LA, HR = 0.48), further biomarker studies are necessary to identify subgroups of better responders and fewer adverse events, prospective studies are needed to identify the potential role of CTLA-4 checkpoint inhibitors combination as first-line treatments for metastatic NSCLC. Anti–CTLA-4 plus anti–PD-L1 or PD-1 may be another choice for patients who cannot tolerate chemo.Table 1Trials of Immunotherapy Plus Chemo in NSCLCKEYNOTE-1891Gandhi L. Rodríguez-Abreu D. Gadgeel S. et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.N Engl J Med. 2018; 378: 2078-2092Google Scholar,20Rodríguez-Abreu D. Powell S.F. Hochmair M.J. et al.Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.Ann Oncol. 2021; 32: 881-895Google ScholarKEYNOTE-4072Paz-Ares L. Luft A. Vicente D. et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.N Engl J Med. 2018; 379: 2040-2051Google Scholar,21Paz-Ares L. Vicente D. Tafreshi A. et al.A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407.J Thorac Oncol. 2020; 15: 1657-1669Google ScholarCheckMate-227 Part 111Hellmann M.D. Paz-Ares L. Bernabe Caro R. et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.N Engl J Med. 2019; 381: 2020-2031Google Scholar,22Paz-Ares L.G. Ramalingam S.S. Ciuleanu T.E. et al.First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, Phase 3 CheckMate 227 Part 1 Trial.J Thorac Oncol. 2022; 17: 289-308Google ScholarMYSTIC10Rizvi N.A. Cho B.C. Reinmuth N. et al.Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial.JAMA Oncol. 2020; 6: 661-674Google ScholarCheckMate-9LA13Paz-Ares L. Ciuleanu T.E. Cobo M. et al.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Lancet Oncol. 2021; 22: 198-211Google ScholarPOSEIDON14Johnson M. Cho B.C. Luft A. et al.Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study. Presented at: 2021 IASLC World Conference on Lung Cancer.September 8-14, 2021Google ScholarAll patients410 vs. 206278 vs. 281Nivo + Ipi vs. Chemo 583 vs. 583Nivo + Ipi + Chemo vs. Chemo361 vs 358Durv + Chemo vs. Durv + Trem + Chemo vs. Chemo338 vs. 338 vs. 337mOS, mo22.0 vs. 10.617.1 vs. 11.617.1 vs. 13.915.8 vs. 11.013.3 vs. 14.0 vs. 11.7HR, OS0.600.710.720.720.86 (Durv + Chemo vs. Chemo)0.77 (Durv + Trem + Chemo vs. Chemo)mPFS, mo9.0 vs. 4.98.0 vs. 5.15.1 vs. 5.56.7 vs. 5.35.5 vs. 6.2 vs. 4.8HR, PFS0.490.570.790.670.74 (D + Chemo vs. Chemo)0.72 (Durv + Trem + Chemo vs. Chemo)PD-L1 ≥1% and ≥50%patientsPD-L1 ≥50%132 vs. 70PD-L1 ≥1%176 vs. 177PD-1 ≥1%Nivo + Ipi vs. Nivo vs. Chemo (396 vs. 396 c 397)PD-L1 TC ≥25%Durv vs. Durv + Trem vs. Chemo163 vs. 163 vs. 162PD-L1 ≥1%204 vs. 204PD-L1 ≥1%225 vs. 213 vs. 207mOS, mo27.7 vs. 10.118.9 vs. 12.817.1 vs. 15.7 vs. 14.916.3 vs. 11.9 vs. 12.915.8 vs. 10.9HR, OS0.590.670.76 (Nivo + Ipi vs. Chemo)0.91 (Nivo vs. Chemo)0.76 (Durv vs. Chemo:)0.85 (Durv + Trem vs. Chemo)0.700.79 (Dur v + Chemo vs. Chemo)0.76 (Durv + Trem + Chemo vs. Chemo)mPFS, mo11.1 vs. 4.88.2 vs. 4.65.1 vs. 4.2 vs. 5.64.7 vs. 3.9 vs. 5.47.0 vs. 5.0HR, PFSH0.350.500.81 (Nivo + Ipi vs. Chemo)0.98 (Nivo vs. Chemo)1.05 (Durv + T rem vs. Chemo)0.87 (Durva vs. Chemo)0.67PD-L1 <1%patientsPD-L1 <1%127 vs. 63PD-L1 <1%95 vs. 99PD-L1 <1%Nivo + Ipi vs. Nivo + Chemo vs. Chemo187 vs. 177 vs. 186PD-L1 TC <1%Durv vs. Durv + Trem vs. Chemo:95 vs. 76 vs. 83PD-L1 <1%135 vs. 129PD-L1 TC <1%113 vs. 125 vs. 130mOS, mo17.2 vs. 10.2PD-L1 <1% (part 1b)Nivo + Ipi vs. Nivo + Chemo vs. Chemo187 vs. :177 :vs. 18617.2 vs. 15.2 vs. 12.210.1 vs. 11.9 vs. 10.317.7 vs. 9.8HR, OS0.510.790.64 (Nivo + Ipi vs. Chemo)0.82 (Nivo + Chemo vs. Chemo)0.73 (Durv vs. Chemo)1.18 (Durv + Trem vs. Chemo)0.67NSQ: 0.75SQ: 0.480.99 (Durv + Chemo vs. Chemo)0.77 (D + T + Chemo vs. Chemo)mPFS, mo6.2 vs. 5.16.3 vs. 5.95.1 vs. 5.6 vs. 4.75.8 vs. 4.9HR, PFS0.670.670.74 (Nivo + Ipi vs. Chemo)0.72 (Nivo + Chemo vs. Chemo)0.68Chemo, chemotherapy; Durva, durvalumab; HR, hazard ratio; Ipi, ipilimumab; mOS, median overall survival; mPFS, median progression-free survival; Nivo, nivolumab; NSQ, nonsquamous; OS, overall survival; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; SQ, squamous; Trem, Tremelimumab; TC, tumor cell. Open table in a new tab Chemo, chemotherapy; Durva, durvalumab; HR, hazard ratio; Ipi, ipilimumab; mOS, median overall survival; mPFS, median progression-free survival; Nivo, nivolumab; NSQ, nonsquamous; OS, overall survival; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; SQ, squamous; Trem, Tremelimumab; TC, tumor cell. Ziming Li: Methodology, Investigation, Writing - original draft, Writing - review & editing. Shun Lu: Conceptualization, Methodology, Investigation, Writing - original draft, Writing - review & editing, Validation, Supervision. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLCJournal of Thoracic OncologyVol. 17Issue 3PreviewFirst-line therapy for patients with metastatic NSCLC includes checkpoint inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy. We compared outcomes with combination chemoimmunotherapy versus dual checkpoint inhibition as first-line treatment for patients with metastatic NSCLC. Full-Text PDF Open Access

Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

A Phase I-III Platform Study Evaluating the Safety and Efficacy of Multiple Therapies in Patients with Biomarker-Defined Locally Advanced, Unresectable Stage III Non–small-Cell Lung Cancer (NSCLC).

First-line Nivolumab Plus Ipilimumab with Two Cycles of Chemotherapy Versus Chemotherapy Alone (four Cycles) in Metastatic Non-Small Cell Lung Cancer: CheckMate 9LA 2-Year Patient-Reported Outcomes

Abstract CT217: First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649

Rethinking the Status of Chemotherapy Combined with the Addition of Cytotoxic T-Lymphocyte–Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

Abstract PO2-18-11: Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small Cell Lung Cancer — A Multicentre Single-Arm Phase II Trial

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.

Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.